ES2529105T3 - Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso - Google Patents

Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso Download PDF

Info

Publication number
ES2529105T3
ES2529105T3 ES10831161.4T ES10831161T ES2529105T3 ES 2529105 T3 ES2529105 T3 ES 2529105T3 ES 10831161 T ES10831161 T ES 10831161T ES 2529105 T3 ES2529105 T3 ES 2529105T3
Authority
ES
Spain
Prior art keywords
compound
ethyl
oxy
dimethylamino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10831161.4T
Other languages
English (en)
Spanish (es)
Inventor
Wei-Guo Su
Weihan Zhang
Hong Jia
Yumin Cui
Yongxin Ren
Yang Sai
Zhenping Wu
Wenji Li
Jiangyong Shao
Zhenping Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44029398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2529105(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of ES2529105T3 publication Critical patent/ES2529105T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ES10831161.4T 2009-11-23 2010-11-23 Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso Active ES2529105T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910199259 2009-11-23
CN2009101992592A CN102070618B (zh) 2009-11-23 2009-11-23 一种化合物及其晶体
PCT/CN2010/078997 WO2011060746A1 (en) 2009-11-23 2010-11-23 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Publications (1)

Publication Number Publication Date
ES2529105T3 true ES2529105T3 (es) 2015-02-16

Family

ID=44029398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10831161.4T Active ES2529105T3 (es) 2009-11-23 2010-11-23 Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso

Country Status (19)

Country Link
US (2) US8658658B2 (ref)
EP (1) EP2504331B1 (ref)
JP (1) JP5758399B2 (ref)
KR (1) KR101513784B1 (ref)
CN (2) CN102070618B (ref)
AU (1) AU2010321366B2 (ref)
BR (1) BR112012012138B1 (ref)
CA (1) CA2781066C (ref)
DK (1) DK2504331T3 (ref)
ES (1) ES2529105T3 (ref)
IN (1) IN2012DN04868A (ref)
MX (1) MX2012005926A (ref)
MY (1) MY161749A (ref)
NZ (1) NZ600266A (ref)
PH (1) PH12012500992A1 (ref)
PL (1) PL2504331T3 (ref)
PT (1) PT2504331E (ref)
RU (1) RU2507203C1 (ref)
WO (1) WO2011060746A1 (ref)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
EP3157912B1 (en) * 2014-06-19 2019-02-20 Merial, Inc. Parasiticidal compositions comprising indole derivatives, methods and uses thereof
CN105985326B (zh) * 2015-02-16 2020-04-14 上海宣创生物科技有限公司 嘧啶衍生物晶型ⅲ及其制备方法和用途
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
US20190276439A1 (en) * 2016-11-18 2019-09-12 Hutchison Medipharma Limited Method of treating solid tumors
JP2020164434A (ja) * 2019-03-28 2020-10-08 上野製薬株式会社 ２，６−ナフタレンビス（２−オキサゾリン）の製造方法
CN118593700A (zh) * 2020-03-09 2024-09-06 和记黄埔医药（上海）有限公司 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
BR112023021066A2 (pt) * 2021-04-12 2023-12-12 Mitoimmune Therapeutics Inc Forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composição

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509299A (pt) * 2004-03-30 2007-09-18 Taisho Pharmaceutical Co Ltd composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica
WO2007035309A1 (en) 2005-09-15 2007-03-29 Merck & Co., Inc. Tyrosine kinase inhibitors
SI2154967T1 (sl) * 2007-04-16 2014-06-30 Hutchison Medipharma Enterprises Limited Offshore Group Chambers Derivati pirimidina
CN101289444B (zh) * 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体

Also Published As

Publication number Publication date
NZ600266A (en) 2014-06-27
BR112012012138B1 (pt) 2023-02-07
MX2012005926A (es) 2012-11-23
EP2504331B1 (en) 2014-11-12
CA2781066C (en) 2014-09-16
CN102648194A (zh) 2012-08-22
US20140200232A1 (en) 2014-07-17
JP2013511475A (ja) 2013-04-04
MY161749A (en) 2017-05-15
CN102648194B (zh) 2014-10-29
KR20120097526A (ko) 2012-09-04
CA2781066A1 (en) 2011-05-26
PH12012500992A1 (en) 2016-09-09
CN102070618B (zh) 2013-08-21
JP5758399B2 (ja) 2015-08-05
US8658658B2 (en) 2014-02-25
AU2010321366A1 (en) 2012-06-14
RU2507203C1 (ru) 2014-02-20
CN102070618A (zh) 2011-05-25
BR112012012138A2 (pt) 2017-03-07
US20120270889A1 (en) 2012-10-25
WO2011060746A1 (en) 2011-05-26
RU2012126112A (ru) 2013-12-27
US8946249B2 (en) 2015-02-03
PT2504331E (pt) 2015-02-20
DK2504331T3 (en) 2014-12-08
PL2504331T3 (pl) 2015-04-30
EP2504331A1 (en) 2012-10-03
AU2010321366B2 (en) 2014-07-24
KR101513784B1 (ko) 2015-04-20
AU2010321366A8 (en) 2012-07-05
IN2012DN04868A (ref) 2015-09-25
EP2504331A4 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
ES2529105T3 (es) Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso
JP6676602B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
CN108658873B (zh) 表皮生长因子受体激酶抑制剂的固体形式
US11958838B2 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide
CN103936762B (zh) 吗啉并喹啉类化合物，其制备方法和用途
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
JP2022525780A (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
TW202543642A (zh) Parp1抑制劑的晶型、包含其之組合物、及其製備
HK40115797A (zh) Prmt5-mta抑制剂